A recent article in Healio news by Isabella Hornick summarises a study titled “Exploring the potential benefits of GLP-1 receptor agonists in pulmonary arterial hypertension: Insights from a large database study”, which was presented at the CHEST Annual Meeting October 19-22, 2025 in Chicago.
GLP-1 receptor agonists (Glucagon-Like Peptide-1) are commonly used for diabetes and weight management but may offer cardiovascular and pulmonary benefits in patients with pulmonary arterial hypertension pulmonary arterial hypertension. The study compared outcomes between pulmonary arterial patients treated with GLP-1 receptor agonists and those on SGLT2 (Sodium-Glucose Co-Transporter-2) inhibitors. Findings revealed a significantly lower incidence of right-heart failure in the GLP-1 group, suggesting potential protective effects on right ventricular function. While reductions in mortality and respiratory failure were not statistically significant, these early data highlight the therapeutic potential of GLP-1 drugs in managing pulmonary arterial and associated complications.
Read more at this link on Healio news
Summary by Deger Kesimoglu, volunteer for the Alliance for Pulmonary Hypertension